Topic · 03 of 08

Technology

454 Articles in this topic

All454 stories in Technology

Newest first
Life & Lifestyle

Japan Moves Toward Its First Pig-to-Human Organ Transplant Trial: Can Xenotransplantation Close the Donor Gap?

Meiji University spinout Pormedtec is preparing Japan's first pig-to-human organ transplant trial, now targeted for 2028 at Hokkaido University Hospital and Shonan Kamakura General Hospital. Only about 4% of Japan's 16,000 registered transplant candidates receive an organ each year. In the US, a gene-edited pig kidney has functioned in a patient for more than seven months.

Technology

Japanese Tree Frog Gut Bacteria Wiped Out Colorectal Tumors in Mice: Inside the JAIST Discovery

Researchers at Japan's JAIST found that Ewingella americana, a bacterium from Japanese tree frog intestines, completely eliminated colorectal tumors in mice after a single dose, a 100% complete response rate that outperformed chemotherapy and immunotherapy in the same comparison. Here is what the preclinical study showed, and what it does not yet show.

Society

Japan's METI 2026 Budget Focuses on Generative AI and Next-Generation Nuclear Reactors - Massive Investment in Domestic AI Development

Japan's Ministry of Economy, Trade and Industry allocates approximately 300 billion yen for generative AI in its 2026 budget proposal. Supporting domestic AI development with 1 trillion yen over 5 years in partnership with private companies like SoftBank. Also advancing next-generation nuclear reactor development to strengthen Japan's industrial competitiveness.

Technology

Revolutionary Cancer Drug Surv.m-CRA from Kagoshima University Enters Final Trials | First New Bone Tumor Drug in 30 Years

Kagoshima University's oncolytic virus Surv.m-CRA-1 has entered a Phase 3 physician-led trial for primary malignant bone tumors, aiming at full approval. The therapy acts on cancer stem cells that conventional drugs struggle to reach, offering a possible new option for a cancer that has seen no new drug in over 30 years. Inside the mechanism, the Nippon Zoki licensing deal, the 2027 approval target, and what remains unproven.